IN2012DN05209A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05209A
IN2012DN05209A IN5209DEN2012A IN2012DN05209A IN 2012DN05209 A IN2012DN05209 A IN 2012DN05209A IN 5209DEN2012 A IN5209DEN2012 A IN 5209DEN2012A IN 2012DN05209 A IN2012DN05209 A IN 2012DN05209A
Authority
IN
India
Prior art keywords
crystalline form
bimatoprost
new
date
designated
Prior art date
Application number
Inventor
F Ambrus Gyorgy
Karami Kiomars
Wu Ke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN05209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN05209A publication Critical patent/IN2012DN05209A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • C07C231/24Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/39Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a new crystalline form of bimatoprost, designated as crystalline form 11. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form I1 is readily prepared from crystalline form I.
IN5209DEN2012 2009-11-23 2010-11-19 IN2012DN05209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26347109P 2009-11-23 2009-11-23
PCT/US2010/057494 WO2011063276A1 (en) 2009-11-23 2010-11-19 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof

Publications (1)

Publication Number Publication Date
IN2012DN05209A true IN2012DN05209A (en) 2015-10-23

Family

ID=43639099

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5209DEN2012 IN2012DN05209A (en) 2009-11-23 2010-11-19

Country Status (20)

Country Link
US (2) US8629185B2 (en)
EP (1) EP2504313A1 (en)
JP (2) JP5921439B2 (en)
KR (1) KR20120085330A (en)
CN (2) CN104367580A (en)
AU (1) AU2010321831B2 (en)
BR (1) BR112012012387A2 (en)
CA (1) CA2781698A1 (en)
CL (1) CL2012001339A1 (en)
CO (1) CO6551754A2 (en)
HK (1) HK1207570A1 (en)
IL (2) IL219959A (en)
IN (1) IN2012DN05209A (en)
MX (1) MX2012005968A (en)
NZ (1) NZ600263A (en)
PH (1) PH12012501098A1 (en)
RU (1) RU2577546C2 (en)
UA (1) UA110696C2 (en)
WO (1) WO2011063276A1 (en)
ZA (1) ZA201203883B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005968A (en) * 2009-11-23 2012-08-15 Allergan Inc 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof.
US9238621B2 (en) 2011-06-02 2016-01-19 Chinoin Zrt Processes for the preparation of prostaglandin amides
DK2911623T3 (en) 2012-10-26 2019-10-28 Forsight Vision5 Inc Ophthalmic system for long-term release of drug into the eye
EA028008B1 (en) * 2012-12-19 2017-09-29 Саркоуд Байосайенс Инк. Lfa-1 inhibitor formulations
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS
CN115677549A (en) * 2022-10-27 2023-02-03 神隆医药(常熟)有限公司 Preparation method of bimatoprost chiral isomer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
KR20030046395A (en) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 Method for reducing intraocular pressure using indole derivatives
JP2007517126A (en) * 2003-12-30 2007-06-28 メタボリックス インコーポレイティッド Nucleator
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
MX2012005968A (en) * 2009-11-23 2012-08-15 Allergan Inc 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof.

Also Published As

Publication number Publication date
CO6551754A2 (en) 2012-10-31
US20140113974A1 (en) 2014-04-24
WO2011063276A1 (en) 2011-05-26
PH12012501098A1 (en) 2014-10-14
CA2781698A1 (en) 2011-05-26
UA110696C2 (en) 2016-02-10
MX2012005968A (en) 2012-08-15
JP2013511573A (en) 2013-04-04
AU2010321831B2 (en) 2016-07-07
CN104367580A (en) 2015-02-25
RU2012125185A (en) 2013-12-27
KR20120085330A (en) 2012-07-31
HK1207570A1 (en) 2016-02-05
JP5921439B2 (en) 2016-05-24
RU2577546C2 (en) 2016-03-20
BR112012012387A2 (en) 2019-09-24
US20110152376A1 (en) 2011-06-23
JP2016094471A (en) 2016-05-26
IL239892A0 (en) 2015-08-31
CN102712584A (en) 2012-10-03
EP2504313A1 (en) 2012-10-03
IL219959A (en) 2015-07-30
NZ600263A (en) 2014-08-29
CN102712584B (en) 2014-10-29
US9181176B2 (en) 2015-11-10
CL2012001339A1 (en) 2012-08-10
IL219959A0 (en) 2012-07-31
ZA201203883B (en) 2013-01-31
US8629185B2 (en) 2014-01-14
AU2010321831A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
IN2012DN05209A (en)
IN2012DN02751A (en)
JOP20180102A1 (en) Pharmaceutical composition
UA116809C2 (en) APPLICATION OF AGROCHEMICAL MIXTURES FOR INCREASING THE VITALITY OF THE PLANT
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
MX348325B (en) Galacto-oligosaccharide-containing composition and a method of producing it.
MX360872B (en) Novel compositions for producing cast polyamides.
MX2010004546A (en) Novel pregabalin intermediates and process for preparing them and pregabalin.
MY149154A (en) Novel microbiocides
MX346980B (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds.
MX2009012309A (en) Use of hydrophobins as additives in the crystallization of solids.
SA114350792B1 (en) New crystalline from salt of pemirolast
MX2011011059A (en) Use of propineb as bird repellent.
MX2012010443A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
IN2012DN03104A (en)
UA102816C2 (en) Process for obtaining the crystalline form v of agomelatine
MX376203B (en) A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
EA201400606A1 (en) Polyolefin fiber
IN2014DN03245A (en)
MX342311B (en) New azaspirodecanone compounds as hsl inhibitors.
IN2012DN02000A (en)
MX2010003056A (en) Valomaciclovir polymorphs.
MX344429B (en) New hexahydropyrroloimidazolone compounds.
IN2015DN02648A (en)